PUBLISHER: iData Research Inc. | PRODUCT CODE: 2026706
PUBLISHER: iData Research Inc. | PRODUCT CODE: 2026706
Global Peripheral Vascular Stent Market Report
The global peripheral vascular stent market was valued at $2.9 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 2.8% to reach $3.5 billion by 2032.
This report focuses on the global market for peripheral vascular stents and further segments the market into arterial stents and venous stents. In addition to market size and forecasts, the analysis includes unit sales, procedure numbers, market shares, average selling prices, growth trends, market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused view of one of the most established yet still evolving categories in peripheral vascular intervention.
An important trend shaping this market is the continued adoption of drug-eluting stents for the treatment of peripheral arterial disease. These devices are designed to deliver medication directly at the treatment site, helping reduce restenosis and improving long-term vessel patency. As clinical evidence continues to support their effectiveness in selected peripheral applications, drug-eluting stents are expected to play a larger role in shaping treatment patterns worldwide. At the same time, covered stents and smaller-profile devices are expanding the range of cases that can be treated with stent-based approaches.
Market Overview
The global peripheral vascular stent market includes implantable devices used to support vessel patency in peripheral arteries and veins. These stents are used in a wide range of clinical applications, including iliac disease, femoral-popliteal disease, below-the-knee intervention, venous obstruction and other peripheral vascular conditions where maintaining vessel openness is critical to long-term treatment success.
Peripheral vascular stents remain a core part of endovascular intervention because they provide durable scaffolding and can address recoil, dissection and vessel collapse after angioplasty. However, the market today is more nuanced than it was in earlier years. Physicians are no longer using stents as a default option in every lesion type. Instead, stent choice is increasingly shaped by lesion complexity, anatomical location, expected long-term outcomes and whether future retreatment options need to be preserved.
Another defining feature of the peripheral vascular stent market is the balance between maturity and innovation. Some major stent indications, especially femoral-popliteal and iliac applications, are already well established and have reached a more mature growth stage. At the same time, product development continues to improve performance, particularly through covered designs, lower-profile delivery systems and ongoing research into drug-eluting technologies. This creates a market where growth is still present, but where new value often comes from product mix and technology upgrades rather than dramatic increases in procedure volume alone.
Market Drivers
Increased Penetration of Covered Stents
One of the most important drivers in the global peripheral vascular stent market is the increasing penetration of covered stents. As more covered stents gain approval for use in iliac, renal, superficial femoral artery and AV access procedures, physicians have greater flexibility in how they treat complex disease. Covered stents have become more popular because they can reduce rates of in-stent restenosis and make restenosis easier to manage when it does occur. In many arterial placements, stenosis is often limited to the proximal end, which can simplify retreatment.
Drug-Eluting Stents
Drug-eluting stents are also a major growth driver, even though this segment has faced past disruption. The market experienced a negative shock in 2019, but drug-eluting stents are still expected to be the fastest-growing segment within the broader peripheral vascular stent market over time. Clinical need remains strong, particularly in lesions where reducing restenosis is critical and where long-term patency can justify the higher device cost.
As more clinical studies are released and manufacturers continue to direct innovation toward this category, drug-eluting stents are expected to remain an important area of development. The relatively high price point of each device also means that adoption can have an outsized effect on market value. In addition, the expanding treatment of below-the-knee lesions supports a growing role for higher-performance stent technologies in more difficult anatomies.
Smaller-Diameter and Lower-Profile Stents
Lower-profile stents are helping open the market to procedures that were not previously possible or practical with larger devices. Smaller-diameter systems can be delivered into narrower and harder-to-access vessels, giving physicians more flexibility in treating distal disease and more complex anatomy. This is especially relevant in lower-extremity disease, where access, lesion length and vessel size can make treatment more challenging.
As stent profiles continue to decrease, more patients with critical limb ischemia and other advanced peripheral disease states can be treated with stent-based interventions. This expands the total treatable population and improves the utility of stents across more indications. These design improvements are also part of a wider trend toward more precise and less traumatic intervention.
Market Limiters
Trend Away from Paclitaxel Devices
A key limiter in the peripheral vascular stent market has been the shift away from paclitaxel-based devices following the FDA investigation into paclitaxel use in the periphery. Physician concern after 2019 created a strong negative effect on this segment, especially for drug-eluting technologies tied to paclitaxel. While the market is expected to recover over time, the pace of that recovery depends on renewed physician confidence, continued clinical research and sustained innovation.
Over the longer term, it is expected that the drug platforms used within peripheral drug-eluting stents may evolve. That transition will require more research, clinical study and investment. Until new approaches are fully validated and gain broad physician acceptance, this uncertainty will continue to limit the pace of DES growth compared with earlier expectations.
Market Maturity
Another major limiter is market maturity, especially in femoral-popliteal and iliac stenting. These are two of the largest segments within peripheral arterial stenting, but they are no longer early-growth markets. In many countries, these indications are already well established and procedure growth is now expected to track more closely with the aging population rather than expand at a rapid pace.
This maturity limits upside for the overall category because even when new products enter the market, they often replace or upgrade existing technologies rather than create entirely new volumes. As a result, growth tends to come from product mix improvement, pricing differences and incremental procedural expansion rather than major step changes in demand.
Complications After Stenting
Complications following stent placement also affect market growth. In-stent stenosis remains a common issue after many types of stenting and often requires ongoing management, including thrombectomy procedures and routine diagnostic follow-up to confirm vessel patency and device position. Because a permanently implanted device can complicate future treatment options, many physicians are increasingly selective about when to place a stent.
This has contributed to a broader trend away from permanent implants in some cases. Drug-eluting balloons and combination procedures can offer treatment pathways that preserve more future options and avoid leaving a permanent scaffold behind. As these alternative approaches gain traction, they can reduce the number of cases in which stenting is the preferred first-line solution.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, growth trends, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report is designed to give both strategic and operational visibility into the global peripheral vascular stent market, with enough detail to support forecasting, competitive benchmarking and commercial planning.
Markets Covered and Segmentation
Arterial Stent Market
This segment includes peripheral vascular stents used in arterial indications such as iliac, femoral-popliteal, below-the-knee and other peripheral arterial treatments.
Venous Stent Market
This segment includes stents used to treat venous obstruction and related venous disease applications, an area of growing interest as venous intervention becomes more specialized.
Each segment is analyzed using market value, unit sales, procedure data and average selling prices, with historical trends and forecasts through 2032.
Competitive Analysis
W.L. Gore is one of the leading competitors in the global peripheral vascular stent market, with particular strength in covered stents. Its position has been supported by the successful development and commercialization of the VIABAHN covered stent platform. Incremental improvements, including heparin coating and lower-profile designs, have helped strengthen its performance in this category. The company also benefited from FDA approval of the GORE TIGRIS self-expanding vascular stent for use in the superficial femoral artery and proximal popliteal artery, reinforcing its relevance in peripheral arterial treatment.
Boston Scientific holds a strong position across several important peripheral stent segments. The company has a notable presence in the iliac and renal stent markets through the Express LD iliac stent and Express SD stents. In venous stenting, Boston Scientific is a leading competitor and built on its historical market share with Wallstent to support the launch of the VICI stent. With VICI gaining U.S. approval in 2019, the company remains well positioned to maintain strong market share in both domestic and global markets.
Abbott held the third-leading position in 2025. The company's Xience Prime BTK stent received CE mark approval in 2011 and secured meaningful share in the below-the-knee segment. Abbott Vascular also offers a broad range of balloon-expandable and self-expanding stents used across multiple peripheral indications. This broad product coverage helps the company stay active in both established and more specialized parts of the market.
Overall, competition in the global peripheral vascular stent market is shaped by product breadth, performance in specific lesion categories and the ability to support physicians with differentiated technology in a mature but still important market.
Technology and Practice Trends
One of the most important technology trends in the peripheral vascular stent market is the growing adoption of drug-eluting stents for treating peripheral arterial disease. These devices are designed to release medication directly at the site of implantation, which can reduce restenosis and improve long-term outcomes compared with traditional bare-metal stents in selected cases.
Covered stents are also gaining share as more physicians use them in iliac, renal, SFA and AV access procedures. Their ability to improve outcomes in certain complex lesions continues to support adoption.
Lower-profile stents represent another major trend. Smaller devices allow treatment in narrower and harder-to-reach vessels, expanding the range of peripheral lesions that can be approached with stent-based therapy.
At the same time, physician practice is becoming more selective. Rather than using stents in every lesion type, clinicians are increasingly balancing stenting against balloon-based and combination approaches. This means that future success in the market will depend not just on having a stent portfolio, but on having the right stent technologies for the right clinical scenarios.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
174 pages of detailed market analysis, data tables and forecasts.
Methodology Appendix and Acronym Glossary.
Where are the largest and most stable opportunities in the global peripheral vascular stent market?
How quickly are covered stents and drug-eluting stents changing product mix across arterial and venous applications?
What effect are physician concerns around paclitaxel and post-stenting complications having on future device demand?
How mature are the major stent indications, and where is meaningful growth still expected through 2032?
Which competitors hold the strongest positions in covered stents, venous stents and other high-value categories?
How are average selling prices, unit volumes and treatment trends shaping market value over time?
The Global Peripheral Vascular Stent Market Report from iData Research answers these questions with detailed market sizing, segmentation, competitive analysis and forecast modeling. Use it to benchmark competitors, evaluate regional opportunities and plan for growth in a mature but clinically important vascular device market.
List Of Figures
List Of Charts
Research Methodology
Impact Of Global Tariffs
Peripheral Vascular Stent Market